Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,114 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02008539 | Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101(TREAT-ME 1) | terminated | Phase 1 / Phase 2 | 13 | Apceth GmbH & Co. KGINDUSTRY | 1 | Mar 27, 2017 | clinicaltrials |
| NCT01019174 | Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma(MM_LEN_DEX_CY) | completed | Phase 1 / Phase 2 | 40 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH |
| 1 |
| Feb 20, 2017 |
| clinicaltrials |
| NCT01817738 | Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 197 | CureVacINDUSTRY | 8 | Feb 17, 2017 | clinicaltrials |
| NCT01220271 | A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 / Phase 2 | 75 | Eli Lilly and CompanyINDUSTRY | 3 | Feb 16, 2017 | clinicaltrials |
| NCT01471782 | Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 93 | Amgen Research (Munich) GmbHINDUSTRY | 7 | Feb 8, 2017 | clinicaltrials |
| NCT01188252 | Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies | completed | Phase 1 | 112 | BayerINDUSTRY | 3 | Jan 9, 2017 | clinicaltrials |
| NCT02331875 | Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity | terminated | Phase 1 / Phase 2 | 3 | Innate PharmaINDUSTRY | 2 | Jan 4, 2017 | clinicaltrials |
| NCT01915576 | Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients | completed | Phase 1 | 79 | BayerINDUSTRY | 4 | Dec 28, 2016 | clinicaltrials |
| NCT01335074 | Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | withdrawn | Phase 1 / Phase 2 | 0 | Philipps University MarburgOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT00825149 | A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma(GAUDI) | completed | Phase 1 | 137 | Hoffmann-La RocheINDUSTRY | 6 | Nov 4, 2016 | clinicaltrials |
| NCT01172223 | Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer(LAPADO) | completed | Phase 1 / Phase 2 | 81 | Prof Dirk EllingOTHER | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01641250 | A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia | completed | Phase 1 | 44 | Hoffmann-La RocheINDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT01849666 | A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | completed | Phase 1 | 2 | Hoffmann-La RocheINDUSTRY | 5 | Nov 2, 2016 | clinicaltrials |
| NCT01851824 | A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | completed | Phase 1 | 9 | Hoffmann-La RocheINDUSTRY | 9 | Nov 2, 2016 | clinicaltrials |
| NCT02083679 | Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer | terminated | Phase 1 | 15 | EMD SeronoINDUSTRY | 2 | Oct 25, 2016 | clinicaltrials |
| NCT02104882 | INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study | completed | Phase 1 / Phase 2 | 12 | Universitätsmedizin MannheimOTHER | 1 | Oct 17, 2016 | clinicaltrials |
| NCT00517530 | A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN) | completed | Phase 1 / Phase 2 | 134 | Hoffmann-La RocheINDUSTRY | 2 | Oct 11, 2016 | clinicaltrials |
| NCT01600573 | Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ) | unknown | Phase 1 / Phase 2 | 68 | JSehouliOTHER | 1 | Oct 11, 2016 | clinicaltrials |
| NCT00862836 | Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)(ZACFAST) | terminated | Phase 1 / Phase 2 | 15 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 10, 2016 | clinicaltrials |
| NCT01133977 | E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma | completed | Phase 1 / Phase 2 | 97 | Eisai Inc.INDUSTRY | 5 | Oct 10, 2016 | clinicaltrials |
| NCT01519323 | BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations | terminated | Phase 1 | 6 | Hoffmann-La RocheINDUSTRY | 10 | Oct 10, 2016 | clinicaltrials |
| NCT02605356 | Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | BayerINDUSTRY | 11 | Oct 7, 2016 | clinicaltrials |
| NCT02244502 | Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) | unknown | Phase 1 / Phase 2 | 31 | NovoCure Ltd.INDUSTRY | 4 | Sep 21, 2016 | clinicaltrials |
| NCT00496509 | Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer | completed | Phase 1 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 26, 2016 | clinicaltrials |
| NCT00994123 | A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 162 | Merrimack PharmaceuticalsINDUSTRY | 6 | Aug 22, 2016 | clinicaltrials |
| NCT01915524 | Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 26 | CureVacINDUSTRY | 3 | Aug 5, 2016 | clinicaltrials |
| NCT01808950 | Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 4 | Spirig Pharma Ltd.INDUSTRY | 2 | Jun 22, 2016 | clinicaltrials |
| NCT01218477 | Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) | completed | Phase 1 / Phase 2 | 33 | Bristol-Myers SquibbINDUSTRY | 7 | Jun 17, 2016 | clinicaltrials |
| NCT02076230 | A Phase 1 TH-302 Mass Balance Trial | completed | Phase 1 | 10 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Jun 10, 2016 | clinicaltrials |
| NCT00933777 | SORAVE - Sorafenib and Everolimus in Solid Tumors(SORAVE) | completed | Phase 1 | 36 | University of CologneOTHER | 1 | May 25, 2016 | clinicaltrials |
| NCT01349296 | BIBF 1120 and RAD001 in Solid Tumors - Phase I(BARIS) | completed | Phase 1 | 18 | University of CologneOTHER | 1 | May 20, 2016 | clinicaltrials |
| NCT01108042 | TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer | completed | Phase 1 / Phase 2 | 71 | Orlando Guntinas-Lichius, Prof. Dr. med.OTHER | 1 | May 18, 2016 | clinicaltrials |
| NCT00567879 | A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab | terminated | Phase 1 / Phase 2 | 56 | Novartis PharmaceuticalsINDUSTRY | 6 | May 9, 2016 | clinicaltrials |
| NCT00876044 | A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients(QUTIE) | completed | Phase 1 | 88 | SanofiINDUSTRY | 7 | May 5, 2016 | clinicaltrials |
| NCT01569412 | Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 14 | Krankenhaus NordwestOTHER | 1 | May 5, 2016 | clinicaltrials |
| NCT01744626 | Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 1 | 40 | Celgene CorporationINDUSTRY | 2 | Apr 19, 2016 | clinicaltrials |
| NCT01972750 | Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma(TKI258) | unknown | Phase 1 | 12 | PD Dr. Martin GlasOTHER | 1 | Apr 19, 2016 | clinicaltrials |
| NCT01394354 | Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)(VBDD) | completed | Phase 1 / Phase 2 | 34 | University Hospital FreiburgOTHER | 1 | Apr 6, 2016 | clinicaltrials |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | unknown | Phase 1 | 112 | e-Therapeutics PLCINDUSTRY | 4 | Apr 6, 2016 | clinicaltrials |
| NCT01008475 | EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer(POSEIDON) | completed | Phase 1 / Phase 2 | 232 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 12 | Mar 30, 2016 | clinicaltrials |
| NCT01497821 | AMG 172 First in Human Study in Patients With Kidney Cancer | completed | Phase 1 | 37 | AmgenINDUSTRY | 3 | Mar 25, 2016 | clinicaltrials |
| NCT01808638 | Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)(Atu027-I-02) | completed | Phase 1 / Phase 2 | 29 | Silence Therapeutics GmbHINDUSTRY | 1 | Mar 11, 2016 | clinicaltrials |
| NCT02369029 | BAY1238097, First in Man | terminated | Phase 1 | 8 | BayerINDUSTRY | 6 | Mar 9, 2016 | clinicaltrials |
| NCT00850382 | Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 89 | University of UlmOTHER | 2 | Mar 1, 2016 | clinicaltrials |
| NCT02430363 | Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 | unknown | Phase 1 / Phase 2 | 58 | Medical Research CouncilOTHER_GOV | 10 | Feb 24, 2016 | clinicaltrials |
| NCT01202591 | Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients(GLOW) | completed | Phase 1 / Phase 2 | 127 | AstraZenecaINDUSTRY | 8 | Feb 11, 2016 | clinicaltrials |
| NCT01238770 | Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 10 | Priv.-Doz. Dr. med. Joachim RomOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT01206036 | CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS)(CEPTAS) | completed | Phase 1 / Phase 2 | 19 | Central European Society for Anticancer Drug ResearchOTHER | 1 | Jan 27, 2016 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials